Definition and diagnosis of Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.
Biomarkers
Definition
Diagnosis
Genetics
Imaging
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
30
07
2024
accepted:
05
09
2024
revised:
31
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Accurate definition and operational criteria for diagnosing Parkinson's disease (PD) are crucial for evidence-based, patient-centered care. To offer evidence-based recommendations for defining and diagnosing PD, incorporating contemporary clinical, imaging, biomarker, and genetic insights. The guideline development began with the steering committee establishing key PICO (patient, intervention, comparison, outcome) questions, which were refined by the coauthors. Systematic literature searches identified relevant studies, reviews, and meta-analyses. Recommendations were drafted, evaluated, optimized, and voted upon by the German Parkinson's Guideline Group. Parkinson's disease (PD) is now understood to encompass a broader spectrum of etiologies than previously recognized. Advances in molecular pathogenesis, neuroimaging, and early clinical phenotypes suggest that PD is not a uniform disease entity and is often not idiopathic. This necessitates an updated framework for PD definition and diagnosis. The German Society for Neurology now endorses a broader concept of PD, incorporating both idiopathic and hereditary forms, as opposed to the previously narrower concept of "idiopathic Parkinson syndrome." The revised guidelines recommend using the 2015 Movement Disorders Society diagnostic criteria, emphasize the importance of long-term clinical follow-up for improved diagnostic accuracy, and highlight the significance of non-motor symptoms in clinical diagnosis. Specific recommendations are provided for the use of imaging and fluid biomarkers and genetic testing to support the clinical diagnosis. The updated guidelines from the German Society for Neurology enhance diagnostic accuracy for PD, promoting optimized clinical care.
Sections du résumé
BACKGROUND
BACKGROUND
Accurate definition and operational criteria for diagnosing Parkinson's disease (PD) are crucial for evidence-based, patient-centered care.
OBJECTIVE
OBJECTIVE
To offer evidence-based recommendations for defining and diagnosing PD, incorporating contemporary clinical, imaging, biomarker, and genetic insights.
METHODS
METHODS
The guideline development began with the steering committee establishing key PICO (patient, intervention, comparison, outcome) questions, which were refined by the coauthors. Systematic literature searches identified relevant studies, reviews, and meta-analyses. Recommendations were drafted, evaluated, optimized, and voted upon by the German Parkinson's Guideline Group.
RESULTS
RESULTS
Parkinson's disease (PD) is now understood to encompass a broader spectrum of etiologies than previously recognized. Advances in molecular pathogenesis, neuroimaging, and early clinical phenotypes suggest that PD is not a uniform disease entity and is often not idiopathic. This necessitates an updated framework for PD definition and diagnosis. The German Society for Neurology now endorses a broader concept of PD, incorporating both idiopathic and hereditary forms, as opposed to the previously narrower concept of "idiopathic Parkinson syndrome." The revised guidelines recommend using the 2015 Movement Disorders Society diagnostic criteria, emphasize the importance of long-term clinical follow-up for improved diagnostic accuracy, and highlight the significance of non-motor symptoms in clinical diagnosis. Specific recommendations are provided for the use of imaging and fluid biomarkers and genetic testing to support the clinical diagnosis.
CONCLUSION
CONCLUSIONS
The updated guidelines from the German Society for Neurology enhance diagnostic accuracy for PD, promoting optimized clinical care.
Identifiants
pubmed: 39297986
doi: 10.1007/s00415-024-12687-5
pii: 10.1007/s00415-024-12687-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Mathias Bähr
(M)
Jos Becktepe
(J)
Daniela Berg
(D)
Kathrin Brockmann
(K)
Andrés Ceballos-Baumann
(A)
Joseph Claßen
(J)
Cornelius Deuschl
(C)
Günther Deuschl
(G)
Richard Dodel
(R)
Georg Ebersbach
(G)
Carsten Eggers
(C)
Thilo van Eimeren
(T)
Alessandra Fanciulli
(A)
Bruno Fimm
(B)
Ann-Kristin Folkerts
(AK)
Madeleine Gausepohl
(M)
Alkomiet Hasan
(A)
Wiebke Hermann
(W)
Rüdiger Hilker-Roggendorf
(R)
Matthias Höllerhage
(M)
Wolfgang Jost
(W)
Elke Kalbe
(E)
Jan Kassubek
(J)
Stephan Klebe
(S)
Christine Klein
(C)
Martin Klietz
(M)
Thomas Köglsperger
(T)
Andrea Kühn
(A)
Paul Krack
(P)
Florian Krismer
(F)
Gregor Kuhlenbäumer
(G)
Johannes Levin
(J)
Inga Liepelt-Scarfone
(I)
Paul Lingor
(P)
Kai Loewenbrück
(K)
Matthias Löhle
(M)
Sylvia Maaß
(S)
Walter Maetzler
(W)
Regina Menzel
(R)
Philipp T Meyer
(PT)
Brit Mollenhauer
(B)
Manuela Neumann
(M)
Per Odin
(P)
Tiago Outeiro
(T)
Monika Pötter-Nerger
(M)
René Reese
(R)
Kathrin Reetz
(K)
Olaf Rieß
(O)
Viktoria Ruf
(V)
Anja Schneider
(A)
Christoph Schrader
(C)
Alfons Schnitzler
(A)
Klaus Seppi
(K)
Friederike Sixel-Döring
(F)
Alexander Storch
(A)
Lars Tönges
(L)
Uwe Walter
(U)
Tobias Wächter
(T)
Tobias Warnecke
(T)
Florian Wegner
(F)
Christian Winkler
(C)
Karsten Witt
(K)
Dirk Woitalla
(D)
Kirsten Zeuner
(K)
Informations de copyright
© 2024. The Author(s).
Références
Parkinson J (2002) An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 14(2):223–236
pubmed: 11983801
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752
pubmed: 2841426
pmcid: 1033142
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
pubmed: 1564476
pmcid: 1014720
Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57(8):1497–1499
pubmed: 11673599
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4):861–870
pubmed: 11912118
Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397(10291):2284–2303
pubmed: 33848468
Marras C, Lang A, van de Warrenburg BP et al (2016) Nomenclature of genetic movement disorders: recommendations of the international Parkinson and movement disorder society task force. Mov Disord 31(4):436–457
pubmed: 27079681
Marras C, Lang A, van de Warrenburg BP et al (2017) Nomenclature of genetic movement disorders: recommendations of the international Parkinson and movement disorder society task force. Mov Disord 32(5):724–725
pubmed: 28513081
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601
pubmed: 26474316
Gibb WR, Lees AJ (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 15(1):27–44
pubmed: 2542825
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912
pubmed: 25904081
Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622–634
pubmed: 27786242
Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30(12):1600–1611
pubmed: 26474317
Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34(10):1464–1470
pubmed: 31412427
Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet 386(10004):1683–1697
pubmed: 26595642
pmcid: 5792067
Attems J, Toledo JB, Walker L et al (2021) Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol 141(2):159–172
pubmed: 33399945
pmcid: 7847437
Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11):812–819
pubmed: 17353469
Jankovic J (1989) Parkinsonism-plus syndromes. Mov Disord 4(Suppl 1):S95-119
pubmed: 2657411
Adler CH, Beach TG, Hentz JG et al (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406–412
pubmed: 24975862
pmcid: 4132570
Hopfner F, Mueller SH, Szymczak S et al (2020) Private variants in PRKN are associated with late-onset Parkinson’s disease. Parkinsonism Relat Disord 75:24–26
pubmed: 32442813
McKeith IG, Ferman TJ, Thomas AJ et al (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94(17):743–755
pubmed: 32241955
pmcid: 7274845
Postuma RB, Poewe W, Litvan I et al (2018) Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 33(10):1601–1608
pubmed: 30145797
Daniel SE, Lees AJ (1993) Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165–172
pubmed: 8360656
Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462
pubmed: 24619848
pmcid: 4204150
Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine in the diagnosis and treatment of Parkinsonian tremor. Clin Neuropharmacol 13(4):312–317
pubmed: 2208183
Adler CH, Beach TG, Zhang N et al (2021) Clinical diagnostic accuracy of early/advanced Parkinson disease: an updated clinicopathologic study. Neurol Clin Pract 11(4):e414–e421
pubmed: 34484939
pmcid: 8382425
Clarke CE, Davies P (2000) Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 69(5):590–594
pubmed: 11032609
pmcid: 1763425
Merello M, Nouzeilles MI, Arce GP, Leiguarda R (2002) Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson’s disease diagnosis. Mov Disord 17(4):795–798
pubmed: 12210878
Rossi P, Colosimo C, Moro E, Tonali P, Albanese A (2000) Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 43(2):95–101
pubmed: 10686467
Terroba Chambi C, Rossi M, Bril A et al (2017) Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease. Mov Disord Clin Pract 4(6):824–828
pubmed: 30363402
pmcid: 6174404
Mahlknecht P, Gasperi A, Djamshidian A et al (2018) Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: a population-based 10-year study. Mov Disord 33(3):405–413
pubmed: 29436728
Marin C, Vilas D, Langdon C et al (2018) Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep 18(8):42
pubmed: 29904888
Borghammer P, Just MK, Horsager J et al (2022) A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease. NPJ Parkinsons Dis 8(1):166
pubmed: 36450732
pmcid: 9712280
Attems J, Walker L, Jellinger KA (2015) Olfaction and aging: a mini-review. Gerontology 61(6):485–490
pubmed: 25968962
Marrero-Gonzalez P, Iranzo A, Bedoya D et al (2020) Prodromal Parkinson disease in patients with idiopathic hyposmia. J Neurol 267(12):3673–3682
pubmed: 32676768
Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173
pubmed: 18067173
Sui X, Zhou C, Li J, Chen L, Yang X, Li F (2019) Hyposmia as a predictive marker of Parkinson’s disease: a systematic review and meta-analysis. Biomed Res Int 2019:3753786
pubmed: 31236405
pmcid: 6545790
Iranzo A, Marrero-Gonzalez P, Serradell M, Gaig C, Santamaria J, Vilaseca I (2021) Significance of hyposmia in isolated REM sleep behavior disorder. J Neurol 268(3):963–966
pubmed: 32968939
Ercoli T, Masala C, Cadeddu G, et al (2022) Does olfactory dysfunction correlate with disease progression in Parkinson's Disease? a systematic review of the current literature. Brain Sci 12(5):513. https://doi.org/10.3390/brainsci12050513
doi: 10.3390/brainsci12050513
pubmed: 35624900
pmcid: 9139278
Janzen A, Vadasz D, Booij J et al (2022) Progressive olfactory impairment and cardiac sympathetic denervation in REM sleep behavior disorder. J Parkinsons Dis 12(6):1921–1935
pubmed: 35754288
pmcid: 9535565
He R, Zhao Y, He Y et al (2020) Olfactory dysfunction predicts disease progression in Parkinson’s disease: a longitudinal study. Front Neurosci 14:569777
pubmed: 33381006
pmcid: 7768001
Kang SH, Lee HM, Seo WK, Kim JH, Koh SB (2016) The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson’s disease. J Neurol Sci 368:374–378
pubmed: 27538667
Chen Y, Xue NJ, Fang Y et al (2022) Association of concurrent olfactory dysfunction and probable rapid eye movement sleep behavior disorder with early Parkinson’s disease progression. Mov Disord Clin Pract 9(7):909–919
pubmed: 36247907
pmcid: 9547146
Nalls MA, McLean CY, Rick J et al (2015) Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 14(10):1002–1009
pubmed: 26271532
pmcid: 4575273
Georgiopoulos C, Davidsson A, Engstrom M, Larsson EM, Zachrisson H, Dizdar N (2015) The diagnostic value of dopamine transporter imaging and olfactory testing in patients with Parkinsonian syndromes. J Neurol 262(9):2154–2163
pubmed: 26122543
Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C (2014) Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? Sleep 37(3):431–438
pubmed: 24587564
pmcid: 3920307
Sixel-Doring F, Zimmermann J, Wegener A, Mollenhauer B, Trenkwalder C (2016) The evolution of REM sleep behavior disorder in early Parkinson disease. Sleep 39(9):1737–1742
pubmed: 27306265
pmcid: 4989262
Figorilli M, Marques AR, Meloni M et al (2020) Diagnosing REM sleep behavior disorder in Parkinson's disease without a gold standard: a latent-class model study. Sleep 43(7). https://doi.org/10.1093/sleep/zsz323
Miyamoto T, Miyamoto M (2022) Odor identification predicts the transition of patients with isolated RBD: a retrospective study. Ann Clin Transl Neurol 9(8):1177–1185
pubmed: 35767550
pmcid: 9380141
Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D (1993) Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology 43(5):962–965
pubmed: 8492953
Alonso CCG, Silva FG, Costa LOP, Freitas S (2021) Smell tests to distinguish Parkinson’s disease from other neurological disorders: a systematic review and meta-analysis. Expert Rev Neurother 21(3):365–379
pubmed: 33546569
Stankovic I, Fanciulli A, Kostic VS et al (2021) Laboratory-supported multiple system atrophy beyond autonomic function testing and imaging: a systematic review by the MoDiMSA study group. Mov Disord Clin Pract 8(3):322–340
pubmed: 33816659
pmcid: 8015918
Moscovich M, Heinzel S, Postuma RB et al (2020) How specific are non-motor symptoms in the prodrome of Parkinson’s disease compared to other movement disorders? Parkinsonism Relat Disord 81:213–218
pubmed: 33039276
Iranzo A, Fernandez-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9(2):e89741
pubmed: 24587002
pmcid: 3935943
Keir LHM, Breen DP (2020) REM sleep behaviour disorder in patients without synucleinopathy. J Neurol Neurosurg Psychiatry 91(11):1239–1240
pubmed: 32792340
Abbott SM, Videnovic A (2014) Sleep disorders in atypical Parkinsonism. Mov Disord Clin Pract 1(2):89–96
pubmed: 24955381
pmcid: 4061748
Nomura T, Inoue Y, Takigawa H, Nakashima K (2012) Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson’s disease. Parkinsonism Relat Disord 18(4):394–396
pubmed: 22115673
Arnulf I, Merino-Andreu M, Bloch F et al (2005) REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep 28(3):349–354
pubmed: 16173657
Postuma RB, Pelletier A, Gagnon JF, Montplaisir J (2022) Evolution of prodromal multiple system atrophy from REM sleep behavior disorder: a descriptive study. J Parkinsons Dis 12(3):983–991
pubmed: 35094998
pmcid: 9789475
Iranzo A, Santamaria J, Rye DB et al (2005) Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65(2):247–252
pubmed: 16043794
Post B, Merkus MP, de Haan RJ, Speelman JD, Group CS (2007) Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov Disord 22(13):1839–1851
pubmed: 17595026
Maggi G, Vitale C, Cerciello F, Santangelo G (2023) Sleep and wakefulness disturbances in Parkinson’s disease: a meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Med Rev 68:101759
pubmed: 36708642
De Pablo-Fernandez E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76(4):470–479
pubmed: 30640364
pmcid: 6459129
Chahine LM, Xie SX, Simuni T et al (2016) Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord 27:102–106
pubmed: 27010070
pmcid: 5031362
Papathoma PE, Markaki I, Tang C et al (2022) A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Sci Rep 12(1):2763
pubmed: 35177751
pmcid: 8854576
Pilotto A, Premi E, Paola Caminiti S et al (2018) Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology 90(12):e1029–e1037
pubmed: 29453242
Lill CM, Mashychev A, Hartmann C et al (2016) Launching the movement disorders society genetic mutation database (MDSGene). Mov Disord 31(5):607–609
pubmed: 27156390
Vollstedt EJ, Schaake S, Lohmann K et al (2023) Embracing monogenic Parkinson’s disease: the MJFF global genetic PD cohort. Mov Disord 38(2):286–303
pubmed: 36692014
Puschmann A (2017) New genes causing hereditary Parkinson’s disease or parkinsonism. Curr Neurol Neurosci Rep 17(9):66
pubmed: 28733970
pmcid: 5522513
Funayama M, Ohe K, Amo T et al (2015) CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol 14(3):274–282
pubmed: 25662902
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881
pubmed: 30967444
Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of Parkinsonian disorder. Neurology 88(10):930–937
pubmed: 28179466
pmcid: 5333515
Irwin DJ, Fedler J, Coffey CS et al (2020) Evolution of Alzheimer’s disease cerebrospinal fluid biomarkers in early Parkinson’s disease. Ann Neurol 88(3):574–587
pubmed: 32542885
pmcid: 7497251
Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology 75(12):1055–1061
pubmed: 20720189
pmcid: 2942062
Yoo D, Bang JI, Ahn C et al (2022) Diagnostic value of alpha-synuclein seeding amplification assays in alpha-synucleinopathies: a systematic review and meta-analysis. Parkinsonism Relat Disord 104:99–109
pubmed: 36289019
Iranzo A, Fairfoul G, Ayudhaya ACN et al (2021) Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20(3):203–212
pubmed: 33609478
Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L (2022) Alpha-synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99(5):195–205
pubmed: 35914941